Posted by Michael Wonder on 19 Jan 2023
Radicava (edarvarone) oral suspension receives positive recommendation from CADTH for the treatment of patients with ALS
18 January 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the CADTH Canadian Drug Expert Committee for Radicava oral suspension, the oral formulation of Radicava IV (edaravone), for the treatment of patients with amyotrophic lateral sclerosis.
Mitsubishi Tanabe Pharma Canada is continuing to work closely with stakeholders to make Radicava oral suspension accessible to patients through private insurance and public formularies.
